Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2012
11/28/2012EP2526934A2 Inhibitors of bruton's tyrosine kinase
11/28/2012EP2526933A2 Inhibitors of bruton's tyrosine kinase
11/28/2012EP2526931A1 Wet granulation methods of cetyl myristate and/or cetyl palmitate
11/28/2012EP2526930A1 Vitamin formulation
11/28/2012EP2526928A1 Increased Effectiveness of Allylamine Drug Compounds
11/28/2012EP2526927A1 Biocompatible nano- and microparticles coated with stabilisers for pulmonary application
11/28/2012EP2526926A1 Biocompatible nanopolymer particles with active agents for pulmonary application
11/28/2012EP2526925A1 A dose adjustable oral pump spray or aerosol spray containing memantine
11/28/2012EP2526924A1 A dose adjustable oral pump spray or aerosol spray containing rasagiline
11/28/2012EP2526923A1 Ophthalmic gel of gatifloxacin and preparation method thereof
11/28/2012EP2526784A1 Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition
11/28/2012EP2526783A1 Natural high-potency sweetener compositions with improved temporal profile and/or flavor profile, methods for their formulation, and uses
11/28/2012EP2526774A2 Targeted gene delivery for dendritic cell vaccination
11/28/2012EP2526771A1 Inhibitors of bruton's tyrosine kinase
11/28/2012EP2526111A2 Aloe-emodin derivatives and use thereof for the treatment of cancer
11/28/2012EP2526110A1 Methods for producing amino-substituted glycolipid compounds
11/28/2012EP2526103A1 A process for the preparation of novel porphyrin derivatives and their use as pdt agents and fluorescence probes
11/28/2012EP2526102A1 Inhibitors of pi3 kinase
11/28/2012EP2526101A1 Crystalline forms of a purine derivative
11/28/2012EP2526100A1 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application
11/28/2012EP2526098A1 Nitrogen-containing heteroaryl derivatives
11/28/2012EP2526097A1 Pyrazine derivatives
11/28/2012EP2526096A1 4-phenoxy-nicotinamide or 4-phenoxy-pyrimidine-5-carboxamide compounds
11/28/2012EP2526095A1 Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
11/28/2012EP2526094A1 Therapeutic substituted chlorocyclopentanols
11/28/2012EP2526093A2 Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
11/28/2012EP2526092A1 Amino heteroaryl compounds as beta-secretase modulators and methods of use
11/28/2012EP2526091A1 Derivatives of pyridoxine for inhibiting hiv integrase
11/28/2012EP2526090A2 New anti-malarial agents
11/28/2012EP2526089A2 A method of industrial production of an amorphous form of atorvastatin with a high specific surface area and its use in a dosage form
11/28/2012EP2526084A1 Salicylate fatty acid derivatives
11/28/2012EP2525828A2 Stabilized proteases for use in skin care
11/28/2012EP2525827A1 Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
11/28/2012EP2525811A1 Nutritional formulas containing synbiotics
11/28/2012EP2525802A2 A method of treating sinusitis, including chronic sinusitis
11/28/2012EP2525801A1 Hydrogel of microspheres
11/28/2012EP2525800A1 Enterococcal cell wall components and antibacterial use thereof
11/28/2012EP2525799A2 (20s,22e)-2-methylene-19-nor-22-ene-1alpha,25-dihydroxyvitamin d3 analogs
11/28/2012EP2525798A1 Anaesthetic formulation
11/28/2012EP2525797A1 Methods for treating pain
11/28/2012EP2525796A2 Aqueous solution comprising 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
11/28/2012EP2525795A1 Methods and compositions for improved nerve conduction velocity
11/28/2012EP2525794A1 5-(1h-pyrazol-5-yl)thiazole-based compounds for the treatment of diseases and disorders of the eye
11/28/2012EP2525793A2 Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
11/28/2012EP2525792A1 Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
11/28/2012EP2525791A2 Special composition for the use thereof as a drug
11/28/2012EP2525790A2 Methods and compositions for cell-proliferation-related disorders
11/28/2012EP2525789A1 Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
11/28/2012EP2525788A2 Novel retigabine composition
11/28/2012EP2525786A2 Pramipexole extended release tablets
11/28/2012EP2525785A1 Sustained release tablet formulation containing etodolac
11/28/2012EP2525784A1 Oral lyophilized compositions
11/28/2012EP2525783A1 Improved oral lysophilisates containing pvp/va
11/28/2012EP2525782A2 Formulations of nano-carriers and methods of preparing the same
11/28/2012EP2525780A2 Synthetic nanostructures including nucleic acids and/or other entities
11/28/2012EP2525776A2 Intracameral sustained release therapeutic agent implants
11/28/2012EP2525774A1 New lipo-phosphated or lipo-sulphated compound, compositions comprising it and topical uses thereof
11/28/2012EP2525660A1 Modified release formulation and methods of use
11/28/2012EP2525657A1 Composition for perinatal and neonatal stroke
11/28/2012DE202010017868U1 Kristalline Formen von Febuxostat Crystalline forms of febuxostat
11/28/2012CN1997394B Compositions and methods comprising an EGFL7 antagonist for modulating vascular development
11/28/2012CN1988891B Coated tablet formulation and method
11/28/2012CN1895671B Compound preparation for treating viral liver disease
11/28/2012CN1889965B Use of biocompatible polymers for the preparation of a composition or a medical device
11/28/2012CN1738829B New 2',5'-oligoadenylic acid analog
11/28/2012CN102803511A Materials and methods useful for affecting tumor cell growth, migration and invasion
11/28/2012CN102803493A Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
11/28/2012CN102803492A Treatment Of Tristetraproline (ttp) Related Diseases By Inhibition Of Natural Antisense Transcript To Ttp
11/28/2012CN102803487A Cancer antigen helper peptide
11/28/2012CN102803474A Beta-cell replication promoting compounds and methods of their use
11/28/2012CN102803293A SIGLEC 15 antibodies in treating bone loss-related disease
11/28/2012CN102803288A Influenza a 2009 pandemic h1n1 polypeptide fragments comprising endonuclease activity and their use
11/28/2012CN102803285A Pharmaceutical composition comprising a steroidal[3,2-c]pyrazole derivative and a second pharmaceutically active compound
11/28/2012CN102803282A A method for preparation of the tetrasaccharide lacto-N-neotetraose (lNNT) containing N-acetyllactosamine
11/28/2012CN102803269A Thieno [2,3-b] pyridinedione activators of AMPK and therapeutic uses thereof
11/28/2012CN102803268A Histamine H3 inverse agonists and antagonists and methods of use thereof
11/28/2012CN102803266A Purine compounds
11/28/2012CN102803265A Pyrrolopyrazine kinase inhibitors
11/28/2012CN102803264A 3-substituted-8-substituted-3h imidazo[5,1-d][1,2,3,5-tetrazin-4-one compounds and their use
11/28/2012CN102803263A Purine compounds used as cb2 agonists
11/28/2012CN102803261A Novel substituted bicyclic triazole derivatives as gamma secretase modulators
11/28/2012CN102803260A Substituted polycyclic carbamoylpyridone derivative
11/28/2012CN102803259A 1H-Imidazo[4, 5-c]quinolinone compounds, useful for the treatment of proliferative diseases
11/28/2012CN102803258A Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application
11/28/2012CN102803256A Method for preparing (r)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1h)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives
11/28/2012CN102803255A Novel GPR 119 agonists
11/28/2012CN102803253A 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds
11/28/2012CN102803252A Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
11/28/2012CN102803250A 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of CYP 17
11/28/2012CN102803249A Hepatitis c virus inhibitors
11/28/2012CN102803248A Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists
11/28/2012CN102803247A Novel fumarate salts of a histamine H3 receptor antagonist
11/28/2012CN102803246A HEDGEHOG pathway antagonists and therapeutic applications thereof
11/28/2012CN102803245A Novel Indole, Indazole And Benzimidazole Arylamides As P2X3 And/or P2X2/3 Antagonists
11/28/2012CN102803240A Crystalline forms of febuxostat
11/28/2012CN102803239A Compound having detrusor muscle-contracting activity and urethral sphincter muscle-relaxing activity
11/28/2012CN102803238A Oxadiazole derivatives
11/28/2012CN102803237A Oxazole and thiazole derivatives as alx receptor agonists
11/28/2012CN102803235A Compounds which selectively modulate the CB2 receptor
11/28/2012CN102803234A Antagonism of human formyl peptide receptor for treatment of disease
1 ... 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 ... 7860